Mouse Pathology Facility (MPF)

The intent of this service is to provide an in-depth histological analysis of mice which have been genetically altered (either transgenic "knock-in" or "knock-out" mice). This collaborative Unit was established to both provide a service to molecular biologists, as well as allowing our Assistants in Pathology to partake in research projects taking place in Switzerland. The costs of our analysis is presently assured by our institute, unless a more extensive study must be undertaken. In return we ask that the assistant responsible for the analysis be included on all publications either presenting or citing the results. All projects are supervised by senior staff members. Initially, all organs will be examined by sections stained with Hemotoxylin and Eosin staining. Further examination may require additional procedures, namely immunohistochemistry and/or X-ray analysis. Internal seminars will be set up to discuss difficult to interpret observations. Prior to the initiation of a project we ask that a research agreement be completed and signed. We would also ask that the appropriate references for the gene which was "knocked in" or "knocked out" be provided. Not only should the genetically altered mice be provided, but also the wild type strain from which they were generated. This Unit is supported by the director of the Institute of Pathology, Frederic T. Bosman and the director of Experimental Pathology, Ivan Stamenkovic.

Statistics from first half of 2008

Selected references of papers in which Mouse Pathology has participated

Suvà ML, Riggi N, Stehle JC, Baumer K, Tercier S, Joseph JM, Suvà D, Clément V, Provero P, Cironi L, Osterheld MC, Guillou L, Stamenkovic I. Identification of Cancer Stem Cells in Ewing's Sarcoma. Cancer Res. 2009 Feb 10

Monnier Y, Farmer P, Bieler G, Imaizumi N, Sengstag T, Alghisi GC, Stehle JC, Ciarloni L, Andrejevic-Blant S, Moeckli R, Mirimanoff RO, Goodman SL, Delorenzi M, Rüegg C. CYR61 and alphaVbeta5 integrin cooperate to promote invasion and metastasis of tumors growing in preirradiated stroma. Cancer Res. 2008 Sep 15; 68(18):7323-31.

Riggi N, Suvà ML, Suvà D, Cironi L, Provero P, Tercier S, Joseph JM, Stehle JC, Baumer K, Kindler V, Stamenkovic I. EWS-FLI-1 expression triggers a Ewing's sarcoma initiation program in primary human mesenchymal stem cells. Cancer Res. 2008 Apr 1;68(7):2176-85.

Echchannaoui H, Bianchi M, Baud D, Bobst M, Stehle JC, Nardelli-Haefliger D. Intravaginal immunization of mice with recombinant Salmonella enterica serovar Typhimurium expressing human papillomavirus type 16 antigens as a potential route of vaccination against cervical cancer. Infect Immun. 2008 May; 76(5):1940-51.

Charles RP, Guitard M, Leyvraz C, Breiden B, Haftek M, Haftek-Terreau Z, Stehle JC, Sandhoff K, Hummler E. Postnatal requirement of the epithelial sodium channel for maintenance of epidermal barrier function. J Biol Chem. 2008 Feb 1; 283(5):2622-30.

Riggi N, Cironi L, Provero P, Suvà ML, Stehle JC, Baumer K, Guillou L, Stamenkovic I. Expression of the FUS-CHOP fusion protein in primary mesenchymal progenitor cells gives rise to a model of myxoid liposarcoma. Cancer Res. 2006 Jul 15;66(14):7016-23.

Bacac M, Migliavacca E, Stehle JC, McKee T, Delorenzi M, Coindre JM, Guillou L, Stamenkovic I. A gene expression signature that distinguishes desmoid tumours from nodular fasciitis. J Pathol. 2006 Mar; 208(4):543-53.

Jelinic P, Stehle JC, Shaw P. The testis-specific factor CTCFL cooperates with the protein methyltransferase PRMT7 in H19 imprinting control region methylation. PLoS Biol. 2006 Oct;4(11):e355.

Telephone numbers and email addresses of the people to contact to initiate a study